Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 7

1.

Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer.

Malik F, Korkaya H, Clouthier SG, Wicha MS.

Cell Cycle. 2012 Aug 1;11(15):2780-1. doi: 10.4161/cc.21395. Epub 2012 Aug 1. No abstract available.

2.

LIN28/LIN28B: an emerging oncogenic driver in cancer stem cells.

Zhou J, Ng SB, Chng WJ.

Int J Biochem Cell Biol. 2013 May;45(5):973-8. doi: 10.1016/j.biocel.2013.02.006. Epub 2013 Feb 16. Review.

PMID:
23420006
3.

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18. Review.

PMID:
19022660
4.

How does Lin28 let-7 control development and disease?

Thornton JE, Gregory RI.

Trends Cell Biol. 2012 Sep;22(9):474-82. doi: 10.1016/j.tcb.2012.06.001. Epub 2012 Jul 9. Review.

5.

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL.

Curr Cancer Drug Targets. 2015;14(9):775-93. Review.

PMID:
25435079
6.

Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.

Emde A, Köstler WJ, Yarden Y; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).

Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e49-57. doi: 10.1016/j.critrevonc.2010.09.002. Epub 2010 Oct 15. Review.

7.

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.

Alvarez RH, Hortobagyi GN.

Breast Cancer. 2013 Apr;20(2):103-10. doi: 10.1007/s12282-013-0446-6. Epub 2013 Feb 3. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk